Tag Archives: Gbola Amusa

Audentes Therapeutics (BOLD) Gets a Buy Rating from Chardan Capital

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $50.00. The company’s shares closed last Monday at $27.84. According to TipRanks.com, Amusa is

Chardan Capital Keeps Their Buy Rating on Meiragtx Holdings Plc (MGTX)

In a report released today, Gbola Amusa from Chardan Capital maintained a Buy rating on Meiragtx Holdings Plc (MGTX – Research Report), with a price target of $45. The company’s shares closed last Monday at $18.29. Amusa commented: “We rate

Chardan Capital Sticks to Its Hold Rating for IVERIC bio Inc (ISEE)

Chardan Capital analyst Gbola Amusa reiterated a Hold rating on IVERIC bio Inc (ISEE – Research Report) yesterday and set a price target of $1.25. The company’s shares closed last Monday at $1.11, close to its 52-week low of $1.02.

Chardan Capital Sticks to Its Hold Rating for Adverum Biotechnologies (ADVM)

Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Adverum Biotechnologies (ADVM – Research Report) today and set a price target of $10. The company’s shares closed last Monday at $12. Amusa observed: “We note the “positive” OPTIC results

Analysts Offer Insights on Healthcare Companies: uniQure NV (NASDAQ: QURE) and Emergent Biosolutions (NYSE: EBS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on uniQure NV (QURE – Research Report) and Emergent Biosolutions (EBS – Research Report). uniQure NV (QURE) In a report released today, Gbola Amusa

Audentes Therapeutics (BOLD) Receives a Buy from Chardan Capital

In a report released yesterday, Gbola Amusa from Chardan Capital reiterated a Buy rating on Audentes Therapeutics (BOLD – Research Report), with a price target of $50. The company’s shares closed last Monday at $31.10. According to TipRanks.com, Amusa is